Biology subjects

Townsend, J. P.

Publications and source records attributed to Townsend, J. P..

4 recordsLinked to original sources

bioRxiv2018

Sexual stage-induced long noncoding RNAs in the filamentous fungus Fusarium graminearum

Long noncoding RNA (lncRNA) plays important roles in morphological differentiation and development in eukaryotes. In filamentous fungi, however, little is known about lncRNAs and their roles in sexual development. Here we describe sexual stage-induced lncRNAs during the formation of perithecia, the sexual fruiting bodies of Fusarium graminearum. We have identified 547 lncRNAs whose expression was developmental stage-specific, with about 40% of which peaked during the development of asci, the sac-like structures containing meiospores. A large fraction of the lncRNAs were found to be antisense to mRNAs, forming 300 sense-antisense pairs. Although small RNAs (sRNAs) were produced from these overlapping loci, most of the antisense lncRNAs appeared not to be involved in gene silencing pathways. Genome-wide analysis of sRNA clusters identified many silenced loci at the meiotic stage. However, we found transcriptionally-active sRNA clusters, many of which were associated with lncRNAs. Also, we observed that many antisense lncRNAs and their respective sense transcripts were induced in parallel as the perithecia matured. To identify regulatory components for lncRNA expression, we analyzed mutants defective in the nonsense-mediated decay (NMD) pathway. A subset of the lncRNAs appeared to be targeted by the NMD before the perithecia formation, suggesting a suppressive role of the NMD in lncRNA expression during vegetative stage. This research provides fundamental genomic resources that will spur further investigations on developmental lncRNAs that may play important roles in shaping the fungal fruiting bodies.

developmental biology↗

bioRxiv2017

Effect sizes of somatic mutations in cancer

A major goal of cancer biology is determination of the relative importance of the genomic alterations that confer selective advantage to cancer cells. Tumor sequence surveys have frequently ranked the importance of substitutions to cancer growth by P value or a false-discovery conversion thereof. However, P values are thresholds for belief, not metrics of effect. Their frequent misuse as metrics of effect has often been vociferously decried. Here, we estimate the effect sizes of all recurrent single nucleotide variants in 23 cancer types, quantifying relative importance within and between driver genes. Some of the variants with the highest effect size, such as EGFR L858R in lung adenocarcinoma and BRAF V600E in primary skin cutaneous melanoma, have yielded remarkable therapeutic responses. Quantification of cancer effect sizes has immediate importance to the prioritization of clinical decision-making by tumor boards, selection and design of clinical trials, pharmacological targeting, and basic research prioritization.

cancer biology↗

bioRxiv2017

The Moran coalescent in a discrete one-dimensional spatial model

Among many organisms, offspring are constrained to occur at sites adjacent to their parents. This applies to plants and animals with limited dispersal ability, to colonies of microbes in biofilms, and to other genetically heterogeneous aggregates of cells, such as cancerous tumors. The spatial structure of such populations leads to greater relatedness among proximate individuals while increasing the genetic divergence between distant individuals. In this study, we analyze a Moran coa-lescent in a one-dimensional spatial model where a randomly selected individual dies and is replaced by the progeny of an adjacent neighbor in every generation. We derive a recursive system of equations using the spatial distance among haplotypes as a state variable to compute coalescent probabilities and coalescent times. The coalescent probabilities near the branch termini are smaller than in the unstructured Moran model (except for t = 1, where they are equal), corresponding to longer branch lengths and greater expected pairwise coalescent times. The lower terminal coalescent probabilities result from a spatial separation of lineages, i.e. a coalescent event between a haplotype and its neighbor in one spatial direction at time t cannot co-occur with a coalescent event with a haplotype in the opposite direction at t + 1. The concomitant increased pairwise genetic distance among randomly sampled haplotypes in spatially constrained populations could lead to incorrect inferences of recent diversifying selection or of population bottlenecks when analyzed using an unconstrained coalescent model as a null hypothesis.

genetics↗

bioRxiv2017

The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C

Activating mutations in RAS genes are associated with approximately 20% of all human cancers. New targeted therapies show preclinical promise in inhibiting the KRAS G12C variant, however, concerns exist regarding the effectiveness of such therapies in vivo given the possibilities of existing intratumor heterogeneity or de novo mutation leading to treatment resistance. We performed deep sequencing of 27 KRAS G12 positive lung tumors and found no evidence of other oncogenic mutations within KRAS or within commonly mutated downstream genes that could confer resistance at the time of treatment. Furthermore, we estimate the de novo mutation rate in KRAS position 12 and in genes downstream of KRAS. We find that mutations that confer resistance are about as likely to occur downstream of KRAS as within KRAS. Moreover, we present an approach for estimation of the selection intensity for these point mutations that explains their high prevalence in tumors. Our approach predicts that BRAF V600E would provide the highest fitness advantage for de novo resistant subclones. Overall, our findings suggest that resistance to targeted therapy of KRAS G12C positive tumors is unlikely to be present at the time of treatment and, among the de novo mutations likely to confer resistance, mutations in BRAF, a gene with targeted inhibitors presently available, result in subclones with the highest fitness advantage.\n\nOne Sentence SummaryMutations conferring resistance to KRAS G12C targeted therapy are unlikely to be present at the time of resection, and the likely mechanisms of evolved resistance are predicted be ones that are responsive to therapies that are in development or that are already available.

cancer biology↗